euro-toxicology-2016_scientifictracks-abstracts

3 / 89

Volume 6, Issue 6(Suppl) J Clin Toxicol 2016
ISSN: 2161-0495, JCT an open access journal
Page 35
Notes:
Euro Toxicology 2016
October 24-26, 2016
conferenceseries.com
Toxicology & Applied Pharmacology
October 24-26, 2016 Rome, Italy
7th Euro-Global Summit on
Nanomedicines in the European translational process
Susanne Bremer Hoffmann
Joint Research Centre-European Commission, Italy
In 2013, the World Health Organization (WHO) released an update of the report on “Priority Medicines for Europe and the
World” with the aim to bridge the gap between public health needs and the current research and development priorities.
The European Commission has recognized the opportunities offered by nanotechnology in the health care sector for the
development of new diagnostic/therapeutic concepts and funds a wide range of projects in order to fully exploit the potential
of nanotechnology. These research activities generate ideas, knowledge and prototypes addressing unmet medical needs that
need now to be further progressed into clinical applications. In order to support the translation of such nanomedicines towards
clinical use, the European Nanomedicine Characterization Laboratory (EU-NCL) has been established. The EU-NCL provides
a comprehensive set of characterization tests (physical, chemical, in vitro and in vivo biological properties) allowing researchers
and SMEs to better define critical quality and safety attributes of their products before entering into clinical investigations. The
knowledge base generated by the EU-NCL will additionally support competent authorities to further understand regulatory
needs of this emerging product category and will boost the regulatory science in the field.
Biography
Susanne Bremer Hoffmann holds a PhD degree in Biology obtained for her work on the development of immunotherapies against leukemia. After Post-doctoral
Research at the Federal Institute for Risk Assessment in Germany, she joined the Joint Research Centre of the European Commission and became a Team
Member of the European Centre for the Validation of Alternative Methods (EURL-ECVAM) where she was involved in validation studies of toxicological in vitro
tests. She collaborated in several framework projects including public-private partnerships and is now a Team Member of the EU-NCL assessing the toxic potential
of nanomaterials by using in vitro test.
Susanne Bremer Hoffmann, J Clin Toxicol 2016, 6:6(Suppl)